Skip to main content

Table 3 Median MIDAS score at baseline and follow up in months. Median difference in MIDAS compared to baseline and percentage change in MIDAS compared to baseline. Proportion of patients contributing to the data

From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Time

Baseline Median (Total)

Baseline Median (Tested)

MIDAS Median After

Change (%)

No. of patients completing questionnaires (No. of patients on treatment)

Zero

130.5

130.5

  

174 (174)

1 to 6

130.5

138

55.5

−82.5 (60%)

133 (158)

7 to 12

130.5

119.5

30

−89.5 (75%)

90 (142)

13 to 18

126.5

119

24

−95 (80%)

49 (106)

19 to 24

129

123

27.5

−95.5 (78%)

60 (94)

25 to 30

123

115.5

14.5

−101 (87%)

40 (52)